Abdera Therapeutics
Mike Abrams has a diverse work experience in the pharmaceutical and biotechnology industry. Mike is currently the Chief Scientific Officer at Abdera Therapeutics since September 2020. Prior to this role, they worked as a Consultant and Director in a self-employed capacity since October 2016. From January 2014 to September 2016, they served as the Executive Vice President and Chief Discovery Officer at Tekmira Pharmaceutical Corporation. Before that, they held the position of Director at Tekmira Pharmaceutical Corporation from 2008 to 2014. Mike also served as the VP of R&D and Chief Innovation Officer at CDRD Ventures from September 2012 to December 2013. Mike held the position of Executive Chairman at Indel Therapeutics Inc. from September 2009 to December 2013. From 2009 to 2012, Mike served as the President & CEO of Inimex Pharmaceuticals. Mike also held the position of Executive Chairman at Indel Therapeutics from 2008 to 2009. Mike's career started at AnorMED Inc., where they served as the President & CEO from 1996 to 2006.
Mike Abrams completed their Ph.D. in Chemistry from the Massachusetts Institute of Technology between 1979 and 1983.
This person is not in any offices
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.